Targeting Human C-Type Lectin-like Molecule-1 (CLL1) with a Bispecific Antibody for Immunotherapy of Acute Myeloid Leukemia (pages 9841–9845)
Dr. Hua Lu, Dr. Quan Zhou, Vishal Deshmukh, Dr. Hardeep Phull, Dr. Jennifer Ma, Dr. Virginie Tardif, Dr. Rahul R. Naik, Dr. Claire Bouvard, Dr. Yong Zhang, Dr. Seihyun Choi, Dr. Brian R. Lawson, Dr. Shoutian Zhu, Dr. Chan Hyuk Kim and Dr. Peter G. Schultz
Article first published online: 23 JUL 2014 | DOI: 10.1002/anie.201405353
A bispecific antibody, αCLL1-αCD3, was synthesized using a genetically encoded unnatural amino acid, and shown to recruit cytotoxic T cells to CLL1-positive cells. The reported results validate the clinical potential of CLL1 as an AML-specific antigen for the generation of bispecific antibodies for the treatment of acute myeloid leukemia (AML).